Amodip is a drug owned by CEVA SANTE ANIMALE. It is protected by 1 US drug patent filed in 2036. All patents are active. Details of Amodip’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US11147804 | Active | |
Exclusivity Information
Amodip holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Amodip's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Apr 29, 2031 |
About Amodip
Amodip is a drug
owned by CEVA SANTE ANIMALE
.
Amodip uses
Amlodipine Besylate as the active
ingredient.
Active Ingredient:
Amodip uses
Amlodipine Besylate as the active ingredient.
Check out other Drugs and Companies using
Amlodipine Besylate ingredient.